Navin Fluorine Q1 FY27: Strong growth, steady margins, and a deliberate push into advanced materials

Navin Fluorine International Limited opened FY27 with a sharp step-up in consolidated performance. For the quarter ended June 30, 2026, net revenue from operations rose to INR 1,045.08 crore, up 44% year on year. Operating EBITDA expanded to INR 357.07 crore, up 73%, with an operating EBITDA margin of 34.2%. Profit after tax more than doubled to INR 243.31 crore, up 108%.

The quarter’s message was consistent across the investor presentation and the earnings call. The company is benefiting from momentum in all three operating verticals while running a multi-year capex program that is intended to support growth beyond FY28. In the call, management also highlighted operating cash flows of INR 173 crore for Q1 and stated that the company became net debt free during the quarter.

A quarter where all three engines pulled

Navin Fluorine’s business is organised around three verticals: High Performance Products, Specialty Chemicals, and CDMO. Q1 FY27 did not rely on a single segment to deliver. Each vertical posted strong year-on-year growth.

High Performance Products reported revenue of INR 540 crore versus INR 407 crore in Q1 FY26, a 33% increase. Management attributed this to volume growth and improved realisations and described the pricing environment for HFCs as constructive.

Specialty Chemicals delivered revenue of INR 325 crore compared with INR 219 crore a year earlier, up 48%. The company pointed to sustained growth supported by order visibility, scale-up opportunities across existing molecules, and a pipeline of new launches.

CDMO was the fastest-growing vertical. Revenue rose to INR 180 crore from INR 99 crore in Q1 FY26, a year-on-year increase of 82%. Management said momentum remains strong, backed by the order book and deeper engagement with a European CDMO major.

Capex program: near-term commissioning and medium-term runway

The company’s current capex roadmap spans capacity additions in HFCs, MPP debottlenecking, CDMO expansion, and a set of projects under the emerging advanced materials theme.

In HFCs, Navin Fluorine is executing capex for additional capacity equivalent up to 15,000 MTPA of R32. The investor presentation lists capex of INR 236.5 crore funded through internal accruals, with commissioning expected by Q3 FY27. The company also disclosed a peak revenue potential of about INR 600 to 825 crore per annum for this project.

In Specialty Chemicals, the company is debottlenecking MPP capacity at Dahej to support a new molecule for a global innovator. Capex is INR 75 crore, also funded by internal accruals, with commissioning targeted by Q3 FY27. The presentation notes a purchase order has been received for CY26 and cites peak revenue potential of about INR 140 to 160 crore per annum.

A separate project linked to Chemours is positioned as a bridge into advanced materials. Navin Fluorine is setting up initial commercial capacity to enable adoption of an innovative liquid cooling product. Capex is INR 120 crore, with 35% funded by the customer, and the project is targeted for commissioning by Q2 FY27. Management reiterated the same timeline in the earnings call and maintained confidentiality on further details.

In CDMO, the key capex is cGMP4. The board had approved total cGMP4 capex of INR 288 crore in February 2024. Phase I was operationalised in Q3 FY26. During the call, the company announced it has initiated Phase II capex of INR 125 crore, expected to operationalise by Q4 FY27. The investor presentation also states a target asset turnover of about 3x for this CDMO asset.

Advanced materials: moving from intent to infrastructure

Management has been positioning advanced materials as a future high growth and high margin vertical, leveraging the company’s fluorination chemistry capabilities and R and D base. In Q1 FY27, this narrative gained a clearer execution marker.

The board approved INR 90 crore of capex to set up adoption capacities for advanced materials, funded through internal accruals, with completion by Q2 FY28. In the call, management described advanced materials as focusing on niche applications in sunrise sectors such as data centers, electronics, semiconductors and defense. They also stated the vertical is intended to evolve into a material business unit by the end of the decade.

In the Q&A, management added more detail on how the adoption capacity is expected to work. They said four to five products have already been qualified by customers at lab scale and the adoption facility is meant to enable commercial scale qualification supplies. They framed the process as a portfolio-driven cycle, where products move through qualification stages and then either migrate into existing platforms or justify dedicated commercial capacity.

The company also announced a technology development partnership with DRDO under a TDF project for indigenous process development for a critical defense material. Management did not provide revenue or margin estimates due to confidentiality, but stated that the product has applications beyond defense as well.

Margins: productivity focus and an implied band

Despite rapid growth, consolidated margin was broadly stable quarter-on-quarter. Operating EBITDA margin in Q1 FY27 was 34.2%, nearly flat versus Q4 FY26. In the call, management acknowledged that gross margin can move with raw material costs and supply chain dynamics. They also highlighted that productivity improvements and fixed cost initiatives can help protect EBITDA.

When asked about a normalised run-rate margin outlook, management indicated an EBITDA margin range of about 32% to 33%, plus or minus 1%, supported by operating leverage from upcoming capacities such as the new HFC capacity, MPP debottlenecking and the Chemours project.

What to watch next

Navin Fluorine is entering FY27 with a strong base, improving cash profile, and multiple commissioning milestones ahead. The near-term checkpoints are clear: commissioning of the Chemours project by end of Q2 FY27, commissioning of the additional R32 capacity and MPP debottlenecking by Q3 FY27, and operationalisation of cGMP4 Phase II by Q4 FY27.

At the same time, the bigger medium-term narrative is about whether advanced materials can move from an incubating initiative into a meaningful earnings contributor. The company has committed capital toward adoption capacities, cited an early qualified product set, and outlined target end markets. The next signals are likely to be qualification updates, customer adoption progress, and the timing and scale of any follow-on commercial capex.

For investors, Q1 FY27 stands out not just for the headline growth, but for the company’s attempt to balance three established engines with a fourth, still forming, future-oriented vertical. The company’s stated timelines and asset productivity targets provide a framework for tracking execution over the next several quarters.